Literature DB >> 16938570

Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias.

Maisa Yoshimoto1, Jean-Claude Cutz, Paulo A S Nuin, Anthony M Joshua, Jane Bayani, Andrew J Evans, Maria Zielenska, Jeremy A Squire.   

Abstract

Prostate cancer (CaP) is characterized by the accumulation of both genetic and epigenetic alterations that transform premalignant lesions to invasive carcinoma. However, the molecular events underlying this critical transition are poorly understood. One of the important genes that might play a role in CaP development is the PTEN gene. At the present time, there has been no systematic analysis of the incidence of genomic PTEN deletion by fluorescence in situ hybridization (FISH) in CaP and associated preneoplastic histologic lesions. This study assesses the frequency of PTEN deletion by interphase FISH analysis in CaP and prostatic intra-epithelial neoplasia (PIN). Dual-color FISH was performed using DNA probes for bands 10q23.3 (PTEN locus) and chromosome 10 centromere using 35 radical prostatectomy specimens. PTEN deletions were not found in 3/3 of stroma, 6/6 samples of benign glandular epithelium, and 12/12 samples of low-grade PIN. However, PTEN deletions were found in 3/13 (23%) of high-grade PIN and 24/35 (68%) of CaP. Concordance was observed between PTEN deletion status and the overall cellular PTEN protein expression levels, as assessed by immunohistochemistry. The high frequency of PTEN deletion observed in CaP versus precursor lesions implicates a pivotal role for PTEN haploinsufficiency in the transition from preneoplastic PIN to CaP. Moreover, this observation is an important consideration for novel therapeutic trials in CaP in which biologic efficacy is influenced by the activity level of PTEN. These findings draw attention to the usefulness of this relatively simple FISH assay for future applications in clinical laboratories.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16938570     DOI: 10.1016/j.cancergencyto.2006.04.003

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  68 in total

1.  Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.

Authors:  Justin M Drake; Nicholas A Graham; Tanya Stoyanova; Amir Sedghi; Andrew S Goldstein; Houjian Cai; Daniel A Smith; Hong Zhang; Evangelia Komisopoulou; Jiaoti Huang; Thomas G Graeber; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

2.  Cytogenetically balanced translocations are associated with focal copy number alterations.

Authors:  Spencer K Watson; Ronald J deLeeuw; Doug E Horsman; Jeremy A Squire; Wan L Lam
Journal:  Hum Genet       Date:  2006-10-19       Impact factor: 4.132

3.  Telomere attrition in isolated high-grade prostatic intraepithelial neoplasia and surrounding stroma is predictive of prostate cancer.

Authors:  Anthony Michael Joshua; Bisera Vukovic; Ilan Braude; Sundus Hussein; Maria Zielenska; John Srigley; Andrew Evans; Jeremy Andrew Squire
Journal:  Neoplasia       Date:  2007-01       Impact factor: 5.715

4.  Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway.

Authors:  A Dirican; H Atmaca; E Bozkurt; C Erten; B Karaca; R Uslu
Journal:  Clin Transl Oncol       Date:  2014-07-25       Impact factor: 3.405

5.  mTOR transcriptionally and post-transcriptionally regulates Npm1 gene expression to contribute to enhanced proliferation in cells with Pten inactivation.

Authors:  Rafik Boudra; Rosyne Lagrafeuille; Corinne Lours-Calet; Cyrille de Joussineau; Gaëlle Loubeau-Legros; Cédric Chaveroux; Jean-Paul Saru; Silvère Baron; Laurent Morel; Claude Beaudoin
Journal:  Cell Cycle       Date:  2016-05-18       Impact factor: 4.534

Review 6.  Mouse models of prostate cancer: picking the best model for the question.

Authors:  Magdalena M Grabowska; David J DeGraff; Xiuping Yu; Ren Jie Jin; Zhenbang Chen; Alexander D Borowsky; Robert J Matusik
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

Review 7.  S-phase-coupled apoptosis in tumor suppression.

Authors:  Yong-Jig Cho; Peng Liang
Journal:  Cell Mol Life Sci       Date:  2011-03-25       Impact factor: 9.261

8.  Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.

Authors:  Shidong Jia; Xueliang Gao; Sang Hyun Lee; Sauveur-Michel Maira; Xiaoqiu Wu; Edward C Stack; Sabina Signoretti; Massimo Loda; Jean J Zhao; Thomas M Roberts
Journal:  Cancer Discov       Date:  2012-12-20       Impact factor: 39.397

9.  Killin is a p53-regulated nuclear inhibitor of DNA synthesis.

Authors:  Yong-Jig Cho; Peng Liang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-02       Impact factor: 11.205

10.  Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.

Authors:  Stephen J Murphy; Robert J Karnes; Farhad Kosari; B Edgardo R Parilla Castellar; Benjamin R Kipp; Sarah H Johnson; Simone Terra; Faye R Harris; Geoffrey C Halling; Janet L Schaefer Klein; Aqsa Nasir; Eric Bergstrahl; Laureano J Rangel; William R Sukov; George Vasmatzis; John C Cheville
Journal:  Mod Pathol       Date:  2015-11-27       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.